2 minute read
Multidistrict litigation (MDL No. 3094) involving GLP-1 receptor agonist medications, such as Ozempic, Wegovy, and Mounjaro, is actively moving forward in the Eastern District of Pennsylvania. Plaintiffs allege that the manufacturers failed to warn users about serious health risks, including gastroparesis, intestinal blockages, and vision loss.
As of July 2025, there are around 2,000 active cases in the MDL, with new lawsuits being filed regularly. The exchange of expert reports and depositions is scheduled to continue through the second half of 2025. The first bellwether trial dates are anticipated to be set in early 2026, depending on how pretrial proceedings progress. While no settlements have been reached at this stage, the court’s timeline suggests that critical developments may occur within the next several months.
Signature Injury
The signature injuries alleged in the GLP-1 MDL include severe gastroparesis, intestinal blockages, and vision loss, resulting in significant and often debilitating health impacts linked to the use of these medications.
Contact Us
If you or a loved one has experienced stomach paralysis or severe digestive problems after taking Ozempic, Wegovy, or Mounjouro, call Michael Brady Lynch Firm at 888-585-5970 for a free consultation.
Date: August 15, 2025
Attorney and Editor-in-Chief: Brandon Salter